Exicure
XCUR | NASDAQ
$1.07
-$0.01 (-0.93%)
At close: Nov 16, 2026, 4:00 PM ET
$1.12
+$0.05 (+4.67%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Exicure Company Profile
Company profile explainedCompany Profile
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Key Executives
| Name | Position |
|---|---|
| Jungsoo Kim | Chief Executive Officer, President & Director |
| Young Seung Ko | Chief Operating Officer |
| Devki Sukhtankar | Head of Preclinical Research & Translational Medicine |
| Gyuyeob Lee | Interim CFO & Secretary |
| Joshua Miller | Chief Accounting Officer |
| Niña Caculitan | Head of Clinical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Jul 17, 2026 | 4 | Filing |
| Jul 17, 2026 | SC 13D/A | [Amend] Filing |
| Jun 30, 2026 | 8-K | Current Report |
| Jun 01, 2026 | 8-K | Current Report |
| May 29, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | NT 10-Q | Filing |
| Apr 10, 2026 | 8-K | Current Report |
| Apr 02, 2026 | 8-K | Current Report |
Exicure
| Country | United States |
| IPO Date | May 22, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Jungsoo Kim |
Contact Details
400 Seaport Court Redwood City,
California 94063 United States
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M309 |
| ISIN Number | US30205M3097 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove XCUR